丽珠集团(000513.SZ)：公司司美格鲁肽注射液减重适应症Ⅲ期临床试验已完成入组

Core Viewpoint - Lijun Group has completed the enrollment phase of its phase III clinical trial for the weight loss indication of Semaglutide injection, which is designed in a head-to-head manner with the original product [1] Group 1 - The clinical trial is progressing smoothly with ongoing follow-up [1] - The company will continue to promote project progress through scientific and efficient research strategies [1] - Research results and subsequent application plans will be disclosed in a timely manner according to regulatory requirements [1]